File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL

Conference Paper: Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis

TitleLiver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis
Authors
Issue Date1999
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.transplantjournal.com
Citation
The 25th Annual Scientific Meeting of the American Society of Transplant Surgeons (ASTS), Chicago, IL., 19-21 May 1999. In Transplantation, 1999, v. 67 n. 9, p. S634 How to Cite?
AbstractPURPOSE: We studied the efficacy and safety of a nucleoside analogue lamivudine in prophylaxis against recurrent hepatitis B (HBV) in Asian patients after liver transplantation (LTx). METHODS: From September 1995 to September 1998, 27 Asian patients (age 17-60yr; M:F, 24:3) who were positive for HBsAg from chronic HBV underwent primary LTx using lamivudine prophylaxis. Ten (37%) patients were of UNOS status 1 and 6 (22%) had associated hepatocellular carcinoma. Fifteen patients received oral lamivudine (100 mg daily) for > 30 days (median, 90 days; 54-374 days) before LTx and 12 underwent LTx within 7 days (median, 4 days; 1-7 days) of lamivudine treatment. Sixteen patients were HBeAg-positive and 9 HBVDNA-positive (Quantiplex™ bDNA assay, Chiron Diagnostics) before lamivudine treatment. Six of 16 patients cleared HBeAg and 5 of 9 cleared HBVDNA before LTx. Lamivudine prophylaxis was continued after LTx and Hepatitis B immunoglobulin was not used. RESULTS: Five patients died of causes not related to HBV at 5 to 36 days after OLT. The remaining 22 (82%) patients were followed-up for a median of 15 months (4 to 39 months) after LTX. There was no adverse effect attributed to lamivudine. In 7 patients, HBsAg persisted or reappeared after a period of temporary clearance, and 15 patients remained HbsAg-negative at a median of 17 months after LTx. One (4.5%) patient developed recurrent hepatitis due to a mutant strain at the YMDD locus 397 days after LTx. There was no biochemical or histologic evidence of recurrent hepatitis B in the remaining 21 patients and none had detectable HBVDNA (by PCR) in serum at a median of 17 months (4 to 39 months) after LTx. CONCLUSIONS: At a median follow-up of 15 months, Lamivudine monotherapy is safe and effective in preventing recurrent hepatitis B following LTx in Asians.
DescriptionPoster Presentation
Persistent Identifierhttp://hdl.handle.net/10722/101935
ISSN
2015 Impact Factor: 3.69
2015 SCImago Journal Rankings: 1.699

 

DC FieldValueLanguage
dc.contributor.authorLo, CM-
dc.contributor.authorFan, ST-
dc.contributor.authorLai, CL-
dc.contributor.authorLiu, CL-
dc.contributor.authorYuen, MF-
dc.contributor.authorNg, IOL-
dc.contributor.authorWong, J-
dc.date.accessioned2010-09-25T20:10:24Z-
dc.date.available2010-09-25T20:10:24Z-
dc.date.issued1999-
dc.identifier.citationThe 25th Annual Scientific Meeting of the American Society of Transplant Surgeons (ASTS), Chicago, IL., 19-21 May 1999. In Transplantation, 1999, v. 67 n. 9, p. S634-
dc.identifier.issn0041-1337-
dc.identifier.urihttp://hdl.handle.net/10722/101935-
dc.descriptionPoster Presentation-
dc.description.abstractPURPOSE: We studied the efficacy and safety of a nucleoside analogue lamivudine in prophylaxis against recurrent hepatitis B (HBV) in Asian patients after liver transplantation (LTx). METHODS: From September 1995 to September 1998, 27 Asian patients (age 17-60yr; M:F, 24:3) who were positive for HBsAg from chronic HBV underwent primary LTx using lamivudine prophylaxis. Ten (37%) patients were of UNOS status 1 and 6 (22%) had associated hepatocellular carcinoma. Fifteen patients received oral lamivudine (100 mg daily) for > 30 days (median, 90 days; 54-374 days) before LTx and 12 underwent LTx within 7 days (median, 4 days; 1-7 days) of lamivudine treatment. Sixteen patients were HBeAg-positive and 9 HBVDNA-positive (Quantiplex™ bDNA assay, Chiron Diagnostics) before lamivudine treatment. Six of 16 patients cleared HBeAg and 5 of 9 cleared HBVDNA before LTx. Lamivudine prophylaxis was continued after LTx and Hepatitis B immunoglobulin was not used. RESULTS: Five patients died of causes not related to HBV at 5 to 36 days after OLT. The remaining 22 (82%) patients were followed-up for a median of 15 months (4 to 39 months) after LTX. There was no adverse effect attributed to lamivudine. In 7 patients, HBsAg persisted or reappeared after a period of temporary clearance, and 15 patients remained HbsAg-negative at a median of 17 months after LTx. One (4.5%) patient developed recurrent hepatitis due to a mutant strain at the YMDD locus 397 days after LTx. There was no biochemical or histologic evidence of recurrent hepatitis B in the remaining 21 patients and none had detectable HBVDNA (by PCR) in serum at a median of 17 months (4 to 39 months) after LTx. CONCLUSIONS: At a median follow-up of 15 months, Lamivudine monotherapy is safe and effective in preventing recurrent hepatitis B following LTx in Asians.-
dc.languageeng-
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.transplantjournal.com-
dc.relation.ispartofTransplantation-
dc.rightsThis is a non-final version of an article published in final form in (provide complete journal citation)-
dc.titleLiver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis-
dc.typeConference_Paper-
dc.identifier.emailLo, CM: chungmlo@hku.hk-
dc.identifier.emailFan, ST: stfan@hku.hk-
dc.identifier.emailLai, CL: hrmelcl@hku.hk-
dc.identifier.emailLiu, CL: clliu@hkucc.hku.hk-
dc.identifier.emailYuen, MF: mfyuen@hku.hk-
dc.identifier.emailNg, IOL: iolng@hku.hk-
dc.identifier.emailWong, J: jwong@hkucc.hku.hk-
dc.identifier.authorityLo, CM=rp00412-
dc.identifier.authorityFan, ST=rp00355-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.authorityYuen, MF=rp00479-
dc.identifier.authorityNg, IOL=rp00335-
dc.identifier.authorityWong, J=rp00322-
dc.identifier.hkuros40649-
dc.identifier.hkuros41177-
dc.identifier.volume67-
dc.identifier.issue9-
dc.identifier.spageS634-
dc.identifier.epageS634-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats